Labcorp Reports Strong Q1 Results, Raises Adjusted EPS Guidance to $18.03
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LH?
Source: PRnewswire
- Significant Revenue Growth: Labcorp achieved total revenue of $3.54 billion in Q1 2026, reflecting a 5.8% year-over-year increase, driven by robust growth in its Diagnostics and Central Laboratory segments, underscoring the company's leadership in complex testing needs.
- Adjusted EPS Guidance Raised: The company raised its 2026 adjusted EPS guidance to $18.03, an increase of $0.13 from previous estimates, reflecting sustained business momentum and effective execution of strategic priorities, thereby enhancing investor confidence.
- Disciplined Capital Allocation: In Q1 2026, Labcorp invested $202.2 million in acquisitions, repurchased $98.0 million in stock, and paid out $61.2 million in dividends, demonstrating the company's disciplined approach to capital allocation and commitment to shareholder returns.
- Technology Investment Drives Innovation: Labcorp's investments in advanced technologies, including robotics and AI, are improving customer experience and transforming operational methods, indicating the company's commitment to enhancing market competitiveness and meeting increasingly complex customer demands.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 259.570
Low
270.00
Averages
304.45
High
325.00
Current: 259.570
Low
270.00
Averages
304.45
High
325.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Labcorp Q1 Earnings Announcement Scheduled
- Earnings Release Date: Labcorp Holdings (LH) is set to announce its Q1 earnings on April 30 before market open, with a consensus EPS estimate of $4.12, reflecting a 12% year-over-year increase, which could boost investor confidence and potentially drive stock price appreciation.
- Revenue Expectations: The anticipated revenue for Q1 is $3.51 billion, representing a 4.8% year-over-year growth, indicating the company's stable growth in the market, which may attract more investor interest in its future prospects.
- Historical Performance Review: Over the past two years, Labcorp has beaten EPS estimates 88% of the time and revenue estimates 63% of the time, and this strong performance record may enhance market expectations for its upcoming earnings report.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 6 upward revisions and 6 downward revisions, while revenue estimates have experienced 5 upward and 4 downward revisions, indicating a divergence in market sentiment regarding Labcorp's future performance, which could influence investor decisions.
See More
Labcorp Q1 Earnings Exceed Expectations
- Earnings Beat: Labcorp reported a Q1 non-GAAP EPS of $4.25, beating expectations by $0.13, which underscores the company's strong profitability and boosts investor confidence.
- Revenue Growth: The company achieved revenue of $3.54 billion, a 5.7% year-over-year increase, exceeding expectations by $30 million, indicating its sustained competitive strength and business expansion capabilities.
- Guidance Raised: Labcorp raised its full-year enterprise revenue guidance to 5.0% to 6.1%, with the midpoint up 20 basis points, and adjusted EPS guidance of $17.70 to $18.35, surpassing the $17.79 consensus by 13 cents, reflecting confidence in future performance.
- Positive Stock Reaction: Following the earnings release, Labcorp's shares rose by 2.3%, demonstrating market recognition of its financial performance and outlook, potentially attracting more investor interest.
See More
Labcorp Reports Strong Q1 Results, Raises Adjusted EPS Guidance to $18.03
- Significant Revenue Growth: Labcorp achieved total revenue of $3.54 billion in Q1 2026, reflecting a 5.8% year-over-year increase, driven by robust growth in its Diagnostics and Central Laboratory segments, underscoring the company's leadership in complex testing needs.
- Adjusted EPS Guidance Raised: The company raised its 2026 adjusted EPS guidance to $18.03, an increase of $0.13 from previous estimates, reflecting sustained business momentum and effective execution of strategic priorities, thereby enhancing investor confidence.
- Disciplined Capital Allocation: In Q1 2026, Labcorp invested $202.2 million in acquisitions, repurchased $98.0 million in stock, and paid out $61.2 million in dividends, demonstrating the company's disciplined approach to capital allocation and commitment to shareholder returns.
- Technology Investment Drives Innovation: Labcorp's investments in advanced technologies, including robotics and AI, are improving customer experience and transforming operational methods, indicating the company's commitment to enhancing market competitiveness and meeting increasingly complex customer demands.
See More
U.S. Stocks Near All-Time Highs as Investors Eye Tech Giants' Earnings
- Strong Market Performance: The S&P 500 and Nasdaq Composite indices reached new all-time highs in April, rising over 8% and 13% respectively, indicating robust market resilience despite ongoing geopolitical tensions and AI disruption concerns, reflecting investor confidence in tech stocks.
- Earnings Pressure on Tech Giants: Next week, five of the 'Magnificent Seven' companies will report earnings, with market expectations for them to demonstrate sufficient revenue growth to justify their high AI expenditures; Alphabet, Amazon, Meta, and Microsoft have all seen stock price increases of over 10% this month, highlighting the market's keen interest in their performance.
- Federal Reserve Meeting Impact: This is expected to be Jerome Powell's last meeting as chair, with the market widely anticipating that the Fed will keep interest rates unchanged, although rising oil prices could complicate future monetary policy, necessitating close attention to how this dynamic may affect the market.
- Cautious Investor Sentiment: As the traditional market adage 'Sell in May' approaches, investors remain wary of potential downside risks, particularly in light of poor software stock performance and rising oil prices, which could further dampen market sentiment.
See More
Labcorp Launches PD-L1 IHC 22C3 Diagnostic for Ovarian Cancer
- New Diagnostic Tool Launch: Labcorp announces the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 diagnostic, the only FDA-approved companion diagnostic to identify patients with platinum-resistant ovarian cancer eligible for Merck's KEYTRUDA®, thereby offering new hope for patients.
- Expanded Treatment Options: KEYTRUDA and its combination drug KEYTRUDA QLEX are the first FDA-approved PD-1 inhibitors that significantly reduce the risk of disease progression and improve survival rates, providing critical treatment options for the approximately 80% of ovarian cancer patients who experience recurrence after initial therapy.
- Rapid Testing Support: Labcorp participated in Agilent's Early Validation Program, enabling quick expansion of PD-L1 IHC 22C3 testing availability through standardized training and readiness activities, ensuring timely identification of eligible patients for clinicians following FDA approval.
- Industry Impact: As a global leader in laboratory services, Labcorp employs nearly 71,000 people and serves clients in approximately 100 countries, supporting over 85% of new drugs and therapeutic products approved in 2025, further solidifying its significant role in the healthcare industry.
See More
Labcorp Launches Nationwide Availability of PD-L1 IHC 22C3 Diagnostic for Ovarian Cancer
- New Diagnostic Tool Launch: Labcorp announces the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 diagnostic, the only FDA-approved companion diagnostic to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA®, thereby providing new hope for patients.
- Expanded Treatment Options: KEYTRUDA and its combination drug KEYTRUDA QLEX are the first FDA-approved PD-1 inhibitors that significantly reduce the risk of disease progression and improve survival rates, particularly relevant for the 80% of ovarian cancer patients who experience recurrence after initial therapy, highlighting their clinical importance.
- Rapid Testing Support: Labcorp participated in Agilent's Early Validation Program, enabling rapid expansion of PD-L1 IHC 22C3 testing availability through standardized training and readiness activities, ensuring quick access for clinicians following FDA approval, thus enhancing treatment opportunities for patients.
- Global Service Capability: With nearly 71,000 employees worldwide, Labcorp supports over 85% of new drugs and therapeutic products approved by the FDA in 2025, showcasing its robust capabilities in diagnostics and drug development, further solidifying its leadership position in the healthcare industry.
See More
Labcorp Q1 Earnings Announcement Scheduled
- Earnings Release Date: Labcorp Holdings (LH) is set to announce its Q1 earnings on April 30 before market open, with a consensus EPS estimate of $4.12, reflecting a 12% year-over-year increase, which could boost investor confidence and potentially drive stock price appreciation.
- Revenue Expectations: The anticipated revenue for Q1 is $3.51 billion, representing a 4.8% year-over-year growth, indicating the company's stable growth in the market, which may attract more investor interest in its future prospects.
- Historical Performance Review: Over the past two years, Labcorp has beaten EPS estimates 88% of the time and revenue estimates 63% of the time, and this strong performance record may enhance market expectations for its upcoming earnings report.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 6 upward revisions and 6 downward revisions, while revenue estimates have experienced 5 upward and 4 downward revisions, indicating a divergence in market sentiment regarding Labcorp's future performance, which could influence investor decisions.
See More
Labcorp Q1 Earnings Exceed Expectations
- Earnings Beat: Labcorp reported a Q1 non-GAAP EPS of $4.25, beating expectations by $0.13, which underscores the company's strong profitability and boosts investor confidence.
- Revenue Growth: The company achieved revenue of $3.54 billion, a 5.7% year-over-year increase, exceeding expectations by $30 million, indicating its sustained competitive strength and business expansion capabilities.
- Guidance Raised: Labcorp raised its full-year enterprise revenue guidance to 5.0% to 6.1%, with the midpoint up 20 basis points, and adjusted EPS guidance of $17.70 to $18.35, surpassing the $17.79 consensus by 13 cents, reflecting confidence in future performance.
- Positive Stock Reaction: Following the earnings release, Labcorp's shares rose by 2.3%, demonstrating market recognition of its financial performance and outlook, potentially attracting more investor interest.
See More
Labcorp Reports Strong Q1 Results, Raises Adjusted EPS Guidance to $18.03
- Significant Revenue Growth: Labcorp achieved total revenue of $3.54 billion in Q1 2026, reflecting a 5.8% year-over-year increase, driven by robust growth in its Diagnostics and Central Laboratory segments, underscoring the company's leadership in complex testing needs.
- Adjusted EPS Guidance Raised: The company raised its 2026 adjusted EPS guidance to $18.03, an increase of $0.13 from previous estimates, reflecting sustained business momentum and effective execution of strategic priorities, thereby enhancing investor confidence.
- Disciplined Capital Allocation: In Q1 2026, Labcorp invested $202.2 million in acquisitions, repurchased $98.0 million in stock, and paid out $61.2 million in dividends, demonstrating the company's disciplined approach to capital allocation and commitment to shareholder returns.
- Technology Investment Drives Innovation: Labcorp's investments in advanced technologies, including robotics and AI, are improving customer experience and transforming operational methods, indicating the company's commitment to enhancing market competitiveness and meeting increasingly complex customer demands.
See More
U.S. Stocks Near All-Time Highs as Investors Eye Tech Giants' Earnings
- Strong Market Performance: The S&P 500 and Nasdaq Composite indices reached new all-time highs in April, rising over 8% and 13% respectively, indicating robust market resilience despite ongoing geopolitical tensions and AI disruption concerns, reflecting investor confidence in tech stocks.
- Earnings Pressure on Tech Giants: Next week, five of the 'Magnificent Seven' companies will report earnings, with market expectations for them to demonstrate sufficient revenue growth to justify their high AI expenditures; Alphabet, Amazon, Meta, and Microsoft have all seen stock price increases of over 10% this month, highlighting the market's keen interest in their performance.
- Federal Reserve Meeting Impact: This is expected to be Jerome Powell's last meeting as chair, with the market widely anticipating that the Fed will keep interest rates unchanged, although rising oil prices could complicate future monetary policy, necessitating close attention to how this dynamic may affect the market.
- Cautious Investor Sentiment: As the traditional market adage 'Sell in May' approaches, investors remain wary of potential downside risks, particularly in light of poor software stock performance and rising oil prices, which could further dampen market sentiment.
See More
Labcorp Launches PD-L1 IHC 22C3 Diagnostic for Ovarian Cancer
- New Diagnostic Tool Launch: Labcorp announces the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 diagnostic, the only FDA-approved companion diagnostic to identify patients with platinum-resistant ovarian cancer eligible for Merck's KEYTRUDA®, thereby offering new hope for patients.
- Expanded Treatment Options: KEYTRUDA and its combination drug KEYTRUDA QLEX are the first FDA-approved PD-1 inhibitors that significantly reduce the risk of disease progression and improve survival rates, providing critical treatment options for the approximately 80% of ovarian cancer patients who experience recurrence after initial therapy.
- Rapid Testing Support: Labcorp participated in Agilent's Early Validation Program, enabling quick expansion of PD-L1 IHC 22C3 testing availability through standardized training and readiness activities, ensuring timely identification of eligible patients for clinicians following FDA approval.
- Industry Impact: As a global leader in laboratory services, Labcorp employs nearly 71,000 people and serves clients in approximately 100 countries, supporting over 85% of new drugs and therapeutic products approved in 2025, further solidifying its significant role in the healthcare industry.
See More
Labcorp Launches Nationwide Availability of PD-L1 IHC 22C3 Diagnostic for Ovarian Cancer
- New Diagnostic Tool Launch: Labcorp announces the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 diagnostic, the only FDA-approved companion diagnostic to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA®, thereby providing new hope for patients.
- Expanded Treatment Options: KEYTRUDA and its combination drug KEYTRUDA QLEX are the first FDA-approved PD-1 inhibitors that significantly reduce the risk of disease progression and improve survival rates, particularly relevant for the 80% of ovarian cancer patients who experience recurrence after initial therapy, highlighting their clinical importance.
- Rapid Testing Support: Labcorp participated in Agilent's Early Validation Program, enabling rapid expansion of PD-L1 IHC 22C3 testing availability through standardized training and readiness activities, ensuring quick access for clinicians following FDA approval, thus enhancing treatment opportunities for patients.
- Global Service Capability: With nearly 71,000 employees worldwide, Labcorp supports over 85% of new drugs and therapeutic products approved by the FDA in 2025, showcasing its robust capabilities in diagnostics and drug development, further solidifying its leadership position in the healthcare industry.
See More
